Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/12172

Title:	Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Authors:	Martínez-Cuadrón, David Boluda, Blanca Martínez, Pilar Bergua, Juan Rodríguez-Veiga, Rebeca Esteve, Jordi Vives, Susana Serrano, Josefina Vidriales, Belen Salamero, Olga Cordón, Lourdes Sempere, Amparo Jiménez-Ubieto, Ana Prieto-Delgado, Julio Díaz-Beyá, Marina Garrido, Ana Benavente, Celina Pérez-Simón, José Antonio Moscardó, Federico Sanz, Miguel A Montesinos, Pau CETLAM and PETHEMA groups
Issue Date:	2018
Abstract:	The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández in the original article.The original version of this article was revised: The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández.
URI:	http://hdl.handle.net/10668/12172
metadata.dc.identifier.doi:	10.1007/s00277-018-3277-x
Appears in Collections:	Producción 2020

Files in This Item:

There are no files associated with this item.

This item is protected by original copyright

Show full item record Recommend this item

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.

RISalud